1 BTC
=
- USD
MoonLake Immunotherapeutics Class A Ordinary Shares
As of May 30, 2026 at 24:05 UTC
Chart
About MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Market Statistics
Trading Metrics
How to Buy MLTX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MLTX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesMoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 150,000 shares worth approximately $2.8 million on April 10-13, 2026, reducing his direct holdings by 4.9%. While the sale is not necessarily alarming given his substantial remaining stake of nearly 3 million shares, the company remains a high-risk investment. MoonLake's stock has fallen 47.47% over the past year following disappointing clinical trial results for its lead therapy Sonelokimab, though the FDA granted it fast-track designation. The pre-revenue biotech company burns approximately $65 million quarterly but has $394 million in cash reserves.
BVF Partners L.P., a biotech-focused hedge fund, sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $63 million on April 2, 2026, reducing its direct stake by 78.3%. The sale appears to be portfolio rebalancing rather than a full exit, as BVF retains 15.9 million shares. MoonLake, a clinical-stage immunotherapy company developing sonelokimab for inflammatory diseases, has experienced a 53.35% stock decline over the past year despite recent positive clinical trial results.
MoonLake Immunotherapeutics announced Week 40 results from its Phase 3 VELA clinical trials of sonelokimab (SLK) for moderate-to-severe hidradenitis suppurativa (HS). The drug demonstrated continued clinical improvement with 62% of patients achieving HiSCR75 response and up to 32% achieving HiSCR100. Patients also showed substantial improvements in quality of life measures, with up to 25% achieving inflammatory remission. No new safety signals were detected. The company expects to present detailed results at the 2026 AAD Annual Meeting and has upcoming milestones including 52-week data readout and BLA submission in H2 2026.
MoonLake Immunotherapeutics has rallied over 30% in the past month following FDA regulatory victories. The company received Fast Track designation for Sonelokimab in treating Palmoplantar Pustulosis and FDA confirmation that existing data is sufficient for approval in Hidradenitis Suppurativa. With $380.5 million in cash runway extending into late 2027, the company has de-risked its investment profile. An upcoming Investor Day on February 23, 2026 will showcase Phase 2 trial data, with potential short squeeze dynamics given 12.7% short interest.
MoonLake Immunotherapeutics announced that the FDA has granted Fast Track designation for sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP), based on positive Phase 2 LEDA trial results. The designation enables more frequent FDA interactions and potential expedited review pathways. The company will discuss this milestone and provide updates on multiple clinical programs at an Investor Day on February 23, 2026, including Phase 2 S-OLARIS data in axial spondyloarthritis and progress toward a BLA submission for hidradenitis suppurativa in H2 2026.